Compare MDLZ & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MDLZ | REGN |
|---|---|---|
| Founded | 2000 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 78.9B | 73.9B |
| IPO Year | N/A | 1991 |
| Metric | MDLZ | REGN |
|---|---|---|
| Price | $54.34 | $755.77 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 18 | 23 |
| Target Price | $68.39 | ★ $795.74 |
| AVG Volume (30 Days) | ★ 10.0M | 1.1M |
| Earning Date | 02-03-2026 | 02-03-2026 |
| Dividend Yield | ★ 3.70% | 0.47% |
| EPS Growth | N/A | ★ 2.88 |
| EPS | 2.69 | ★ 41.59 |
| Revenue | ★ $37,645,000,000.00 | $14,247,800,000.00 |
| Revenue This Year | $7.35 | $1.95 |
| Revenue Next Year | $4.04 | $5.47 |
| P/E Ratio | $20.07 | ★ $17.82 |
| Revenue Growth | ★ 4.13 | 2.89 |
| 52 Week Low | $53.13 | $476.49 |
| 52 Week High | $71.15 | $790.98 |
| Indicator | MDLZ | REGN |
|---|---|---|
| Relative Strength Index (RSI) | 36.21 | 61.81 |
| Support Level | $53.13 | $689.88 |
| Resistance Level | $56.33 | $753.61 |
| Average True Range (ATR) | 1.02 | 20.54 |
| MACD | -0.06 | -4.09 |
| Stochastic Oscillator | 26.96 | 65.15 |
Mondelez has operated independently since its split from the former Kraft Foods North American grocery business in October 2012. The firm is a leading player in the global snack enclave with a presence in the biscuit (49% of sales as of the end of fiscal 2024), chocolate (31%), gum/candy (11%), beverage (3%), and cheese and grocery (6%) aisles. Mondelez's portfolio includes well-known brands like Oreo, Chips Ahoy, Halls, and Cadbury. The firm derives around one-third of its revenue from developing markets, just more than one-third from Europe, and the remainder from North America.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).